About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Vaccine Can Protect One-third African Infants Against Malaria

by VR Sreeraman on November 11, 2012 at 8:06 PM
Font : A-A+

 New Vaccine Can Protect One-third African Infants Against Malaria

A large-scale Phase III trial has found that the newly developed RTS,S candidate vaccine can help protect African infants against malaria.

When compared to immunization with a control vaccine, infants (aged 6-12 weeks at first vaccination) vaccinated with RTS,S had one-third fewer episodes of both clinical and severe malaria and had similar reactions to the injection. In this trial, RTS,S demonstrated an acceptable safety and tolerability profile.

Advertisement

Eleven African research centers in seven African countries are conducting this trial, together with GlaxoSmithKline (GSK) and the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill and Melinda Gates Foundation to MVI.

"This study indicates that RTS,S can help to protect young babies against malaria. Importantly, we observed that it provided this protection in addition to the widespread use of bed nets by the trial participants," said Dr. Salim Abdulla, a principal investigator for the trial from the Ifakara Health Institute, Tanzania.
Advertisement

When administered along with standard childhood vaccines, the efficacy of RTS,S in infants aged 6 to 12 weeks (at first vaccination) against clinical and severe malaria was 31 percent and 37 percent respectively, over 12 months of follow-up after the third vaccine dose.

Insecticide-treated bed nets were used by 86 percent of the trial participants, which demonstrated that RTS,S provided protection beyond existing malaria control interventions.

The efficacy observed with RTS,S last year in children aged 5-17 months of age against clinical and severe malaria was 56 percent and 47 percent, respectively. Follow-up in this Phase III trial will continue and is expected to provide more data for analyses to better understand the different findings between the age categories.

The vaccine is being developed in partnership by GSK and MVI, together with prominent African research centers.

The study has been published online in the New England Journal of Medicine.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Malaria-water Malaria Mosquito Diseases Vaccination for Children Fever Top 10 Vaccine Myths Debunked 

Most Popular on Medindia

The Essence of Yoga Drug Side Effects Calculator Iron Intake Calculator Indian Medical Journals Drug - Food Interactions Color Blindness Calculator Find a Hospital A-Z Drug Brands in India Vent Forte (Theophylline) Noscaphene (Noscapine)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use